Search results
Results From The WOW.Com Content Network
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, [3] is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. [4] [5] [6] The company ranked 100th in the Fortune India 500 list in 2020. [7]
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates , finished formulations , food supplements, biotechnology products and pharmaceutical machinery.
Cadila Healthcare began phase II trials of the vaccine candidate from 6 August 2021 with over 1,000 volunteers as part of the adaptive Phase I/II multi-centric, dose escalation, randomised, double-blind placebo controlled method. [10] [11] [12] The company reported that phase II trials were completed by November 2020. [13] [14]
In 2006, Cadila Healthcare acquired a 14.96% stake in the company. [10] Cadila's stake in the company increased to over 70% in 2008, after the merger of Cadila's consumer goods business, which included sugar substitute brand Sugar Free and EverYuth range of skincare products, into Carnation. [11]
When he took over the Cadila Healthcare, he was faced with two challenges: His was a Rs 200-crore company whereas his overheads including management, research, company expenses, and staff worked out to Rs 400 crore. It was difficult to make two ends meet. [4] They were the first Indian company to develop a drug for high-cholesterol diabetics.
Indravadan Ambalal Modi (18 February 1926 – 26 November 2012) [1] was an Indian pharmaceuticals industrialist who founded Cadila Pharmaceuticals in Ahmedabad.He is popularly known as the 'Medicine Man of India' for his contribution to the pharmaceutical industry of India post independence.
Gujarat has become a hub for the pharmaceutical industry, with several established companies such as Torrent Pharmaceuticals, Zydus Lifesciences, Cadila Pharmaceuticals, Alembic Pharmaceuticals, Sun Pharma, Claris, Intas Pharmaceuticals, and Dishman Pharmaceuticals having operations in the state.
India's Cadila Healthcare has started producing its potential COVID-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to ...